Clovis Oncology Inc (CLVS), ACADIA Pharmaceuticals Inc. (ACAD): Three Humongous Health-Care Stocks This Week

Page 2 of 2

The better news for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s stock was announced on Thursday morning. An SEC filing by Baker Bros. Advisors disclosed a 22.6% stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Baker Bros. Advisors is a hedge fund that holds significant positions in a number of biotechs, including previously mentioned Clovis Oncology.

Best pick
Which of this week’s stars looks to be the best pick now? I’ll go with Clovis Oncology Inc (NASDAQ:CLVS).

Granted, the stock could see a pullback after the tremendous pop this week. And we’re still looking only at phase 1 results for rucaparib. There’s a lot that can happen in the days ahead that could derail the company’s success.

But this is biotech. Risks are part of the game. If rucaparib experiences positive results in later-stage studies, this humongous week for Clovis could turn into a humongous decade.

The article 3 Humongous Health-Care Stocks This Week originally appeared on Fool.com is written by Keith Speights.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2